Viral Vector Manufacturing Market by Type (Retrovirus, Gammaretrovirus, AAV), Disease (Cancer, Infectious Disease, Genetic Disorders), Application (Gene Therapy, Vaccinology), End User (Biotech companies, Research Institutes) - Global Forecasts to 2023
The global viral vector manufacturing market is projected to reach USD 815.8 million by 2023, at a CAGR of 20.0%. Some key factors driving market growth include the rising prevalence of target diseases and disorders, the availability of funding for gene therapy development, effectiveness of viral vectors in gene therapy delivery, and ongoing research into viral vector-based gene & cell therapies. Untapped potential in emerging markets is expected to offer lucrative growth opportunities for players in the market.
Objectives of the Study
- To define, describe, and forecast the global viral vector manufacturing market by type, disease, application, end user, and region
- To provide detailed information about the major factors influencing market growth (drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of market segments with respect to five main regions, namely, North America, Europe, Asia Pacific, and Rest of the World (RoW)
- To profile key players and comprehensively analyze their core competencies in terms of key market developments, product portfolios, and financials
- To track and analyze competitive developments such as product launches, collaborations, partnerships and agreements, acquisitions, expansions, and other developments in the market
Research Methodology
Top-down and bottom-up approaches were used to validate the size of overall viral vector manufacturing industry and estimate the size of other dependent submarkets. Various secondary sources such as Source: Annual Reports, SEC Filings, Investor Presentations, World Health Organization (WHO), National Institutes of Health (NIH), US Food and Drug Administration (FDA), American Society of Gene & Cell Therapy (ASGCT), European Medicines Agency (EMA), European Society for Gene and Cell Therapy (ESGCT), World Bank, Academic Journals, Company Websites, Expert Interviews, Annual Reports, SEC Filings, Investor Presentations, and MarketsandMarkets Analysis have been used to identify and collect information useful for the study of this market. Primary sources such as experts from both supply and demand sides have been interviewed to obtain and validate information as well as to assess the dynamics of this market. The breakdown of profiles of primaries is shown in the figure below:
The major players in the global market are Lonza (Switzerland), Merck (Germany), Oxford BioMedica (UK), CGT Catapult (UK), Cobra Biologics (UK), uniQure (Netherlands), FUJIFILM Diosynth Biotechnologies (US), and Spark Therapeutics (US).
Target Audience:
- Pharmaceutical and biotechnology companies
- Viral vector developers
- Contract development and manufacturing organizations (CDMOs)
- Business research and consulting firms
- Research institutions
- Venture capitalists
Viral Vector Manufacturing Market Scope
The research report categorizes the market into the following segments and subsegments:
By Type
- Retroviral Vectors
- Adenoviral Vectors
- Adeno-associated Viral Vectors
- Other Viral Vectors
By Disease
- Cancers
- Genetic Disorders
- Infectious diseases
- Other Diseases
By Application
- Gene Therapy
- Vaccinology
By End User
- Pharmaceutical and Biopharmaceutical Companies
- Research Institutes
By Region
-
North America
- US
- Canada
-
Europe
- UK
- Germany
- France
- Rest of Europe (RoE)
- Asia Pacific (APAC)
- Rest of the World
Available customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Geographical Analysis
- Further breakdown of the market into APAC and RoE countries
Company Information
- Detailed analysis and profiling of additional market players (Up to 5)
In this report, the global market is segmented by type, disease, application, end user. By type, the market is segmented into retroviral vectors, adenoviral vectors, adeno-associated viral vectors, and other viral vectors. The adeno-associated viral vector manufacturing segment is expected to grow at the highest CAGR during the forecast period as they have applications in most cell-based gene therapies.
Based on disease, the market is segmented into cancer, genetic disorders, infectious diseases, and other diseases. In 2018, cancer is expected to account for the largest share of the global market. Its large share can be attributed to growing research on viral vector gene therapies for cancer.
By application, the viral vector manufacturing market is segmented into gene therapy and vaccinology. The gene therapy segment is expected to grow at the highest rate during the forecast period. The availability of effective viral vector gene therapies for rare diseases and cancers, ongoing research activities on viral vector gene therapies, and the recent approval of several viral vector gene therapies are driving the growth of this market.
Based on end users, the viral vector manufacturing market is segmented into pharmaceutical and biopharmaceutical companies and research institutes. In 2018, pharmaceutical and biopharmaceutical companies are expected to account for the largest share of the global market. The successful launch of viral vector gene therapies and a robust pipeline of such therapies are the key factors contributing to the growth of the pharmaceutical and biopharmaceutical companies segment during the forecast period.
Geographically, Asia Pacific is expected to grow at the fastest rate viral vector manufacturing market during the forecast period. The fast growth of this regional segment can be attributed to the growing research activities to launch novel gene therapies in the untapped markets of this region.
While the overall market is expected to grow during the forecast period, the high price of gene therapies and short shelf-life of viral vectors are likely to restrain the growth of this market to a certain extent. The major players in the global market include Lonza (Switzerland), Merck (Germany), Oxford BioMedica (UK), CGT Catapult (UK), Cobra Biologics (UK), uniQure (Netherlands), FUJIFILM Diosynth Biotechnologies (US), and Spark Therapeutics (US).
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
Table of Contents
1 Introduction (Page No. - 11)
1.1 Objectives of the Study
1.2 Market Definition
1.2.1 Markets Covered
1.2.2 Years Considered for the Study
1.3 Currency
1.4 Stakeholders
2 Research Methodology (Page No. - 14)
2.1 Primary Data
2.1.1 Key Data From Primary Sources
2.1.2 Key Industry Insights
2.2 Secondary Data
2.2.1 Key Data From Secondary Sources
2.3 Market Size Estimation
2.4 Market Breakdown and Data Triangulation
2.5 Assumptions for the Study
3 Executive Summary (Page No. - 22)
4 Premium Insights (Page No. - 24)
4.1 Market Overview
5 Market Overview (Page No. - 25)
5.1 Introduction
5.2 Evolution
5.3 Market Dynamics
5.3.1 Drivers
5.3.1.1 Rising Prevalence of Genetic Disorders, Cancer, and Infectious Diseases
5.3.1.2 Availability of Funding for the Development of Gene Therapy
5.3.1.3 Effectiveness of Viral Vectors
5.3.1.4 Ongoing Research Into Viral Vector-Based Gene and Cell Therapies
5.3.2 Restraints
5.3.2.1 High Costs Associated With Gene Therapy
5.3.2.2 Short Shelf-Life of Viral Vectors
5.3.3 Challenges
5.3.3.1 Risk of Mutagenesis and Other Unwanted Outcomes
6 Viral Vector Manufacturing Market, By Type (Page No. - 31)
6.1 Introduction
6.2 Retroviral Vectors
6.2.1 Lentiviral Vectors
6.2.2 Gamma-Retroviral Vectors
6.3 Adenoviral Vectors
6.4 Adeno-Associated Viral Vectors
6.5 Other Viral Vectors
7 Viral Vector Manufacturing Market, By Disease (Page No. - 40)
7.1 Introduction
7.2 Cancer
7.3 Genetic Disorders
7.4 Infectious Diseases
7.5 Other Diseases
8 Viral Vector Manufacturing Market, By Application (Page No. - 47)
8.1 Introduction
8.2 Gene Therapy
8.3 Vaccinology
9 Viral Vector Manufacturing Market, By End User (Page No. - 51)
9.1 Introduction
9.2 Pharmaceutical and Biopharmaceutical Companies
9.3 Research Institutes
10 Viral Vector Manufacturing Market, By Region (Page No. - 55)
10.1 Introduction
10.2 North America
10.3 Europe
10.4 Asia Pacific
10.5 Rest of the World
11 Competitive Landscape (Page No. - 68)
11.1 Overview
11.1.1 Product Approval
11.1.2 Collaborations, Partnerships, and Agreements
11.1.3 Acquisitions and Mergers
11.1.4 Expansions
12 Company Profiles (Page No. - 71)
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
12.1 Lonza
12.2 Merck KGaA
12.3 Oxford Biomedica
12.4 Cobra Biologics
12.5 Novasep
12.6 Spark Therapeutics
12.7 Kaneka Eurogentec
12.8 Finvector Vision Therapies
12.9 Brammer Bio
12.10 Cell and Gene Therapy Catapult (CGT Catapult)
12.11 Fujifilm Holdings Corporation
12.12 Uniqure
12.13 Regenxbio
12.14 Massbiologics
*Details on Marketsandmarkets View, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments Might Not Be Captured in Case of Unlisted Companies.
13 Appendix (Page No. - 99)
13.1 Insights of Industry Experts
13.2 Discussion Guide
13.3 Knowledge Store: Marketsandmarkets’ Subscription Portal
13.4 Introducing RT: Real-Time Market Intelligence
13.5 Available Customizations
13.6 Related Reports
13.7 Author Details
List of Tables (50 Tables)
Table 1 Approved Viral Vector Gene Therapies
Table 2 Number of Clinical Trials Registered on Various Viral Vectors Globally
Table 3 Viral Vector Manufacturing Market, By Type, 2016–2023 (USD Million)
Table 4 Market for Retroviral Vectors, By Type, 2016–2023 (USD Million)
Table 5 Market for Retroviral Vectors, By Region, 2016–2023 (USD Million)
Table 6 Market for Lentiviral Vectors, By Region, 2016–2023 (USD Million)
Table 7 Viral Vector Manufacturing Market for Gamma-Retroviral Vectors, By Region, 2016–2023 (USD Million)
Table 8 Market for Adenoviral Vectors, By Region, 2016–2023 (USD Million)
Table 9 Viral Vector Manufacturing Market for Adeno-Associated Viral Vectors, By Region, 2016–2023 (USD Million)
Table 10 Gene Therapy Applications of Other Viral Vectors
Table 11 Market for Other Viral Vectors, By Region, 2016–2023 (USD Million)
Table 12 Viral Vector Manufacturing Market, By Disease, 2016–2023 (USD Million)
Table 13 Market for Cancer, By Region, 2016–2023 (USD Million)
Table 14 Phase Iii/Iv Clinical Trials Based on Monogenic Diseases
Table 15 Market for Genetic Disorders, By Region, 2016–2023 (USD Million)
Table 16 Viral Vector Manufacturing Market for Infectious Diseases, By Region, 2016–2023 (USD Million)
Table 17 Market for Other Diseases, By Region, 2016–2023 (USD Million)
Table 18 Viral Vector Manufacturing Market, By Application, 2016–2023 (USD Million)
Table 19 Market for Gene Therapy, By Region, 2016–2023 (USD Million)
Table 20 Viral Vector Vaccines Pipeline
Table 21 Viral Vector Manufacturing Market for Vaccinology, By Region, 2016–2023 (USD Million)
Table 22 Market, By End User, 2016–2023 (USD Million)
Table 23 Market for Pharmaceutical and Biopharmaceutical Companies, By Region, 2016–2023 (USD Million)
Table 24 Viral Vector Manufacturing Market Size for Academic Research Institutes, By Region, 2016–2023 (USD Million)
Table 25 Market, By Region, 2016–2023 (USD Million)
Table 26 North America: Market, By Type, 2016–2023 (USD Million)
Table 27 North America: Market for Retroviral Vectors, By Type, 2016–2023 (USD Million)
Table 28 North America: Viral Vector Manufacturing Market, By Disease, 2016–2023 (USD Million)
Table 29 North America: Market, By Application, 2016–2023 (USD Million)
Table 30 North America: Viral Vector Manufacturing Market, By End User, 2016–2023 (USD Million)
Table 31 Europe: Market, By Type, 2016–2023 (USD Million)
Table 32 Europe: Viral Vector Manufacturing Market for Retroviral Vectors, By Type, 2016–2023 (USD Million)
Table 33 Europe: Market, By Disease, 2016–2023 (USD Million)
Table 34 Europe: Viral Vector Manufacturing Market, By Application, 2016–2023 (USD Million)
Table 35 Europe: Market, By End User, 2016–2023 (USD Million)
Table 36 APAC: Viral Vector Manufacturing Market, By Type, 2016–2023 (USD Million)
Table 37 APAC: Market for Retroviral Vectors, By Type, 2016–2023 (USD Million)
Table 38 APAC: Market, By Disease, 2016–2023 (USD Million)
Table 39 APAC: Viral Vector Manufacturing Market, By Application, 2016–2023 (USD Million)
Table 40 APAC: Market, By End User, 2016–2023 (USD Million)
Table 41 RoW: Viral Vector Manufacturing Market, By Type, 2016–2023 (USD Million)
Table 42 RoW: Market for Retroviral Vectors, By Type, 2016–2023 (USD Million)
Table 43 RoW: Market, By Disease, 2016–2023 (USD Million)
Table 44 RoW: Market, By Application, 2016–2023 (USD Million)
Table 45 RoW: Market, By End User, 2016–2023 (USD Million)
Table 46 Rank of Companies in the Global Viral Vector Market, 2018
Table 47 New Approval , 2015–2018
Table 48 Agreements, Partnerships and Collaborations, 2015–2018
Table 49 Acquisitions 2015-2018
Table 50 Expansions, 2015–2018
List of Figures (22 Figures)
Figure 1 Research Design
Figure 2 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 3 Market Size Estimation Methodology: Bottom-Up Approach
Figure 4 Market Size Estimation Methodology: Top-Down Approach
Figure 5 Data Triangulation
Figure 6 Retroviral Vectors Dominate the Vira Vectors Manufacturing Market
Figure 7 Geographical Snapshot: High Growth Expected in Emerging APAC Markets During the Forecast Period
Figure 8 Accelerated Research Activities in Gene Therapy Drive the Market
Figure 9 Cancer to Dominate the Viral Vectors Manufacturing Market By Disease (2018)
Figure 10 Timeline for Major Events in Gene Therapy
Figure 11 Viral Vectors Manufacturing Market: Drivers, Restraints, and Challenges
Figure 12 Adeno-Associated Viral Vectors: Targeted Therapies
Figure 13 Gene Therapy Research Targets
Figure 14 Number of Gene Therapies in Various Clinical Trial Phases
Figure 15 Lonza: Company Snapshot
Figure 16 Merck KGaA: Company Snapshot
Figure 17 Oxford Biomedica: Company Snapshot
Figure 18 Spark Therapeutics: Company Snapshot
Figure 19 Kaneka Corporation: Company Snapshot (2017)
Figure 20 Fujifilm Holdings Corporation: Company Snapshot (2017)
Figure 21 Uniqure: Company Snapshot (2017)
Figure 22 Regenxbio: Company Snapshot (2017)
Growth opportunities and latent adjacency in Viral Vector Manufacturing Market